
    
      An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose,
      crossover bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER
      Tablets of Dr. Reddy's and Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals Inc., USA
      in healthy, adult, human subjects under fed conditions.
    
  